JP7824885B2 - 表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体 - Google Patents

表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体

Info

Publication number
JP7824885B2
JP7824885B2 JP2022563981A JP2022563981A JP7824885B2 JP 7824885 B2 JP7824885 B2 JP 7824885B2 JP 2022563981 A JP2022563981 A JP 2022563981A JP 2022563981 A JP2022563981 A JP 2022563981A JP 7824885 B2 JP7824885 B2 JP 7824885B2
Authority
JP
Japan
Prior art keywords
dcn
tcrk
decorin
skin
epidermolysis bullosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022563981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523719A (ja
JP2023523719A5 (https=
Inventor
テロ ヤルヴィネン
トイニ ペンマリ
ウルリケ マイ
Original Assignee
タンペレ ユニバーシティー ファウンデーション エスアール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タンペレ ユニバーシティー ファウンデーション エスアール filed Critical タンペレ ユニバーシティー ファウンデーション エスアール
Publication of JP2023523719A publication Critical patent/JP2023523719A/ja
Publication of JP2023523719A5 publication Critical patent/JP2023523719A5/ja
Application granted granted Critical
Publication of JP7824885B2 publication Critical patent/JP7824885B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022563981A 2020-04-28 2021-04-28 表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体 Active JP7824885B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063016359P 2020-04-28 2020-04-28
FI20205431 2020-04-28
US63/016,359 2020-04-28
FI20205431 2020-04-28
PCT/FI2021/050318 WO2021219940A1 (en) 2020-04-28 2021-04-28 Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa

Publications (3)

Publication Number Publication Date
JP2023523719A JP2023523719A (ja) 2023-06-07
JP2023523719A5 JP2023523719A5 (https=) 2024-05-07
JP7824885B2 true JP7824885B2 (ja) 2026-03-05

Family

ID=75870661

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563981A Active JP7824885B2 (ja) 2020-04-28 2021-04-28 表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体

Country Status (10)

Country Link
US (1) US20230167162A1 (https=)
EP (1) EP4142771A1 (https=)
JP (1) JP7824885B2 (https=)
KR (1) KR20230005314A (https=)
CN (1) CN115605218B (https=)
AU (1) AU2021266157A1 (https=)
BR (1) BR112022021879A2 (https=)
CA (1) CA3180694A1 (https=)
IL (1) IL297703A (https=)
WO (1) WO2021219940A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118001404B (zh) * 2024-02-06 2025-02-25 四川大学华西医院 抑制C17orf67基因表达试剂在制备治疗获得性大疱表皮松解症药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors

Also Published As

Publication number Publication date
CN115605218A (zh) 2023-01-13
CA3180694A1 (en) 2021-11-04
BR112022021879A2 (pt) 2022-12-20
JP2023523719A (ja) 2023-06-07
WO2021219940A1 (en) 2021-11-04
AU2021266157A1 (en) 2022-12-08
CN115605218B (zh) 2026-03-24
EP4142771A1 (en) 2023-03-08
IL297703A (en) 2022-12-01
US20230167162A1 (en) 2023-06-01
KR20230005314A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
ES2744225T3 (es) Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
US20180112193A1 (en) Csf1 therapeutics
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
JP6339231B2 (ja) 線維症性疾患の処置のためのＴｒａｉｌレセプターアゴニスト
JP6876618B2 (ja) 治療目的のための抗体−ウレアーゼコンジュゲート
CN105026432A (zh) 抑肽酶衍生的多肽-抗体缀合物
US20190247317A1 (en) Icam-1 targeting elps
TW202227464A (zh) 治療阿茲海默氏症之多表位疫苗
KR20230141958A (ko) 개선된 치료 지수를 위한 플라스민-내성 펩티드
JP7824885B2 (ja) 表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体
TW202237634A (zh) 用於治療ｃｏｖｉｄ－１９之ｄｓｇ２組成物和方法
CA3020339C (en) Compositions and methods for treating pancreatitis and pain with death receptor agonists
Pemmari et al. Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa
CN118369351A (zh) Dsg2组合物和方法
JP2011529452A (ja) 抗血管新生薬としての可溶性ｉｇｆ受容体
HK1236396A1 (en) Trail receptor agonists for treatment of fibrotic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7824885

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150